We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck's Non-Oncology Drugs Q3 Performance: What to Expect
Read MoreHide Full Article
Key Takeaways
MRK will report Q3 results on Oct. 30, with investors watching the performance of key non-oncology drugs.
Capvaxive and Winrevair saw strong early uptake, boosting MRK's non-oncology growth outlook.
Animal Health growth and new drug launches are likely to support second-half revenues.
Merck (MRK - Free Report) is scheduled to report third-quarter 2025 results on Oct. 30. Investors are likely to focus on the sales performance of its blockbuster cancer drug, Keytruda. The drug accounted for more than 50% of the company’s pharmaceutical sales during the first half of 2025. The company’s other oncology drugs, like Lynparza, Koselugo, Lenvima, and Welireg, are expected to have contributed to top-line growth.
However, with Keytruda facing a looming loss of exclusivity in 2028, investors are closely watching Merck’s non-oncology drugs, mainly its newly approved products, 21-valent pneumococcal conjugate vaccine, Capvaxive and pulmonary arterial hypertension (PAH) drug, Winrevair.
Both Capvaxive and Winrevair witnessed a strong uptake during the first half of 2025. Capvaxive recorded sales of $236 million in the first half of 2025 and Winrevair generated sales worth $615 million during the same time.
We expect these two new drugs to have performed well in the third quarter, given the strong launch they have witnessed so far.
Merck’s Animal Health business is also a key contributor to its top-line growth, as the company is recording above-market growth. Revenues from the Animal Health business are likely to have risen in the third quarter. Our estimates for Animal Health suggest a CAGR of 5.9% over the next three years.
Merck’s newest respiratory syncytial virus (RSV) antibody, Enflonsia (clesrovimab), was approved in the United States in June 2025, while it is under review in the EU. Merck is currently gearing up to launch Enflonsia to help protect infants entering their first RSV season.
A fixed-dose combination of doravirine and islatravir for the treatment of HIV is under review in the United States, with an FDA decision expected in April next year.
MRK's Competition in the Target Market
While Merck’s new products show strong potential, competition in the target market also looms large.
Winrevair is likely to face stiff competition in the PAH market, which remains highly competitive. Significant players in the PAH market are United Therapeutics (UTHR - Free Report) and J&J (JNJ - Free Report) .
J&J’s key PAH drugs include Opsumit and Uptravi. JNJ recorded revenues of $2.14 billion from its PAH franchise in the first half of 2025.
UTHR markets four drugs to treat PAH in the United States — Remodulin, Orenitram, Tyvaso and Adcirca. United Therapeutics’ Remodulin, Orenitram and Tyvaso recorded sales of $272.9 million, $244.6 million and $935.9 million, respectively, in the first half of 2025.
Meanwhile, Enflonsia is also likely to face competition from AstraZeneca/ Sanofi’s RSV antibody Beyfortus, which was also approved for a similar indication in 2023.
Besides antibodies, some other vaccines have been approved for preventing RSV in certain patients in the United States. These include Pfizer’s Abrysvo, GSK’s Arexvy and Moderna’s mRESVIA.
MRK's Price Performance, Valuation and Estimates
Year to date, shares of Merck have declined 12.3% against the industry’s rise of 5.5%. The stock has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Merck appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 9.33 forward earnings, lower than 15.56 for the industry and its 5-year mean of 12.63.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share has decreased from $8.94 per share to $8.92, while the same for 2026 has decreased from $9.55 to $9.44 over the past 60 days.
Image: Bigstock
Merck's Non-Oncology Drugs Q3 Performance: What to Expect
Key Takeaways
Merck (MRK - Free Report) is scheduled to report third-quarter 2025 results on Oct. 30. Investors are likely to focus on the sales performance of its blockbuster cancer drug, Keytruda. The drug accounted for more than 50% of the company’s pharmaceutical sales during the first half of 2025. The company’s other oncology drugs, like Lynparza, Koselugo, Lenvima, and Welireg, are expected to have contributed to top-line growth.
However, with Keytruda facing a looming loss of exclusivity in 2028, investors are closely watching Merck’s non-oncology drugs, mainly its newly approved products, 21-valent pneumococcal conjugate vaccine, Capvaxive and pulmonary arterial hypertension (PAH) drug, Winrevair.
Both Capvaxive and Winrevair witnessed a strong uptake during the first half of 2025. Capvaxive recorded sales of $236 million in the first half of 2025 and Winrevair generated sales worth $615 million during the same time.
We expect these two new drugs to have performed well in the third quarter, given the strong launch they have witnessed so far.
Merck’s Animal Health business is also a key contributor to its top-line growth, as the company is recording above-market growth. Revenues from the Animal Health business are likely to have risen in the third quarter. Our estimates for Animal Health suggest a CAGR of 5.9% over the next three years.
Merck’s newest respiratory syncytial virus (RSV) antibody, Enflonsia (clesrovimab), was approved in the United States in June 2025, while it is under review in the EU. Merck is currently gearing up to launch Enflonsia to help protect infants entering their first RSV season.
A fixed-dose combination of doravirine and islatravir for the treatment of HIV is under review in the United States, with an FDA decision expected in April next year.
MRK's Competition in the Target Market
While Merck’s new products show strong potential, competition in the target market also looms large.
Winrevair is likely to face stiff competition in the PAH market, which remains highly competitive. Significant players in the PAH market are United Therapeutics (UTHR - Free Report) and J&J (JNJ - Free Report) .
J&J’s key PAH drugs include Opsumit and Uptravi. JNJ recorded revenues of $2.14 billion from its PAH franchise in the first half of 2025.
UTHR markets four drugs to treat PAH in the United States — Remodulin, Orenitram, Tyvaso and Adcirca. United Therapeutics’ Remodulin, Orenitram and Tyvaso recorded sales of $272.9 million, $244.6 million and $935.9 million, respectively, in the first half of 2025.
Meanwhile, Enflonsia is also likely to face competition from AstraZeneca/ Sanofi’s RSV antibody Beyfortus, which was also approved for a similar indication in 2023.
Besides antibodies, some other vaccines have been approved for preventing RSV in certain patients in the United States. These include Pfizer’s Abrysvo, GSK’s Arexvy and Moderna’s mRESVIA.
MRK's Price Performance, Valuation and Estimates
Year to date, shares of Merck have declined 12.3% against the industry’s rise of 5.5%. The stock has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Merck appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 9.33 forward earnings, lower than 15.56 for the industry and its 5-year mean of 12.63.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share has decreased from $8.94 per share to $8.92, while the same for 2026 has decreased from $9.55 to $9.44 over the past 60 days.
Image Source: Zacks Investment Research
MRK's Zacks Rank
Merck currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.